Abstract:Abstract Background Bladder cancer (BCa) is the leading reason for death among malignancies in genitourinary system. RNA modifications participate in pivotal tumor-promoting mechanisms in specific epigenetic contexts. Our study aimed to propose a novel model associated with the “writer” enzymes of five primary RNA adenosine modifications (including m6A, m6Am, m1A, alternative polyadenylation, and adenosine-to-inosine editing), which could predict the clinical outcome and immunotherapeutic efficacy of BCa, thus conferring a promising orientation for BCa predictive, preventive, and personalized medicine (PPPM/3PM). Methods Unsupervised clustering was employed to categorize BCa into different RNA modification patterns on the basis of gene expression profiles of 34 RNA modification “writers”. The RNA modification “writers” score (RMS) signature composed of RNA phenotype-associated differentially expressed genes (DEGs) was established using the least absolute shrinkage and selection operator (LASSO). The prognostic power of the RMS model was evaluated using Kaplan-Meier analysis and receiver operating characteristic curves. A visualized nomogram was established for BCa risk stratification. The potential applicability of the RMS model in predicting the therapeutic responsiveness was assessed through the Genomics of Drug Sensitivity in Cancer database and multiple immunotherapy datasets. Results Two distinct RNA modification patterns were determined among 1410 BCa samples, showing radically varying clinical outcomes and biological characteristics. The RMS model comprising 14 RNA modification phenotype-associated prognostic DEGs was positively correlated with the unsatisfactory outcome of BCa patients in a meta-GEO training cohort (HR = 3.00, 95% CI = 2.19–4.12) and the TCGA-BLCA validation cohort (HR = 1.53, 95% CI = 1.13–2.09). The infiltration of immunosuppressive cells and the activation of EMT, angiogenesis, IL-6/JAK/STAT3 signaling were markedly enriched in RMS-high cohort. A nomogram including age, N classification and the RMS exhibited high prognostic prediction accuracy, with a concordance index of 0.745. The combination of the RMS model and conventional characteristics (TMB, TNB and PD-L1) achieved an optimal area under the curve of 0.828 in differentiating responders from non-responders to immunotherapy based on IMvigor210 cohort. Conclusion Our report conferred the first landscape of five forms of RNA modifications in BCa and emphasized the excellent power of the RNA modifications-related model in evaluating prognosis and immunotherapeutic efficacy. In accordance with our model, physicians can not only conduct early identification of high-risk patients to confer them with priority attention and targeted prevention, but also judge patients’ responses to immunotherapy in advance to render personalized therapy, which is conducive to the research and practice of PPPM/3PM in BCa.

Identification of RNA-binding protein RBMS3 as a potential biomarker for immunotherapy in bladder cancer

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Integrating single cell and bulk RNA sequencing data identifies RBM17 as a novel response biomarker for immunotherapy in bladder cancer

Identification of the Six-RNA-Binding Protein Signature for Prognosis Prediction in Bladder Cancer

The construction and validation of an RNA binding protein-related prognostic model for bladder cancer

Identification of the Functions and Prognostic Values of RNA Binding Proteins in Bladder Cancer

Single-cell RNA-binding Protein Pattern-Mediated Molecular Subtypes Depict the Hallmarks of the Tumor Microenvironment in Bladder Urothelial Carcinoma

A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer.

Identification and Validation of an RNA Binding Proteins-Associated Prognostic Signature for Non-Small Cell Lung Cancer

Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity

Integrated Risk Scores from N6-methyladenosine-related Lncrnas Are Potential Biomarkers for Predicting the Overall Survival of Bladder Cancer Patients

Transcriptome Analyses Identify an RNA Binding Protein Related Prognostic Model for Clear Cell Renal Cell Carcinoma

Identification of an Immune-Related RNA-binding Protein Signature to Predict Survival and Targeted Therapy Responses in Liver Cancer.

Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer

Prognostic Value and Immunological Characteristics of a Novel RNA Binding Protein Signature in Cutaneous Melanoma

Development of prognostic signature based on RNA binding proteins related genes analysis in clear cell renal cell carcinoma

Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma

Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer

Identification of a novel immune-related long noncoding RNA signature to predict the prognosis of bladder cancer

Identification of a novel RNA modifications-related model to improve bladder cancer outcomes in the framework of predictive, preventive, and personalized medicine

Identification of RBM15 as a prognostic biomarker in prostate cancer involving the regulation of prognostic m6A-related lncRNAs